- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01170234
Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis
April 11, 2019 updated by: Tufts Medical Center
There is currently no reliable, noninvasive biomarker for eosinophilic esophagitis (EoE), a chronic allergic diseases characterized by significant infiltration of eosinophils in the esophagus.
Because eosinophils release nitric oxide, levels of exhaled nitric oxide (FeNO) are used routinely for guiding treatment in subsets of patients with asthma.
FeNO levels are also elevated in immunological diseases that do not involve the airways.
The investigators hypothesize that patients with EoE have elevated nitric oxide concentration in their exhaled breath and that changes in FeNO levels could be used to measure disease activity.
The objective of this study is to determine the feasibility of using FeNO as a noninvasive surrogate marker for EoE disease activity.
The investigators propose to measure serial exhaled nitric oxide (FeNO) levels on a group of patients with confirmed EoE, before, during and after the course of topical corticosteroid therapy to determine whether the level declines from pre-treatment level in individual patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
14
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 65 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Gastroenterology outpatient clinic
Description
Inclusion Criteria:
- Age 7-65.
- Confirmed diagnosis of EoE. The diagnosis of eosinophilic esophagitis is based upon the presence of characteristic clinical features and large numbers of eosinophils in the esophagus on pathologic examination (≥15 eosinophils per high powered [400x] field in at least one specimen) despite acid suppression with a PPI for one to two months. The criteria also include normal gastric and duodenal mucosal biopsies and the exclusion of other causes. Clinical features in adults include dysphagia, pain and/or history of food impaction. Symptoms in children vary depending in part upon their age: feeding disorders (median age 2.0), vomiting (median age 8.1), abdominal pain (median age 12.0), dysphagia (median age 13.4), and food impaction (median age 16.8).
Exclusion Criteria:
- Use of systemic or inhaled corticosteroids in the preceding 3 months.
- History of doctor-diagnosed asthma, acute or chronic rhinosinusitis.
- History of cirrhosis.
- History of kidney, heart or lung disease.
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Eosinophilic esophagitis (EoE)
Treatment-naïve EoE patients, age 7 -65
|
We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis
Time Frame: 2 years
|
The objective of this study is to determine the feasibility of using exhaled nitric oxide (FeNO) as a noninvasive surrogate marker for EoE disease activity.
We will measure FeNO levels on a group of patients with confirmed EoE before, during and after the course of topical corticosteroid therapy.
|
2 years
|
Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis
Time Frame: 2 years
|
Change in exhaled nitric oxide levels during corticosteroid treatment.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exhaled nitric oxide as a biomarker for disease activity in eosinophilic esophagitis
Time Frame: 2 years
|
Intra- and inter-patient variability in exhaled nitric oxide levels.
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: John Leung, MD, Tufts Medical Center
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
August 1, 2010
Primary Completion (Actual)
February 1, 2012
Study Completion (Actual)
February 1, 2012
Study Registration Dates
First Submitted
July 23, 2010
First Submitted That Met QC Criteria
July 26, 2010
First Posted (Estimate)
July 27, 2010
Study Record Updates
Last Update Posted (Actual)
April 16, 2019
Last Update Submitted That Met QC Criteria
April 11, 2019
Last Verified
April 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TUFTS-EOE-FENO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Eosinophilic Esophagitis
-
Children's Hospital Medical Center, CincinnatiNational Institute of Allergy and Infectious Diseases (NIAID); National Institute... and other collaboratorsCompletedEosinophilic Esophagitis (EoE) | Eosinophilic Gastrointestinal Disorders (EGIDs)United States
-
Federico II UniversityRecruitingEsophagitis, EosinophilicItaly
-
Ann & Robert H Lurie Children's Hospital of ChicagoRecruitingEosinophilic Gastroenteritis | Eosinophilic Esophagitis | Eosinophilic Colitis | Eosinophilic Gastrointestinal DiseaseUnited States
-
Medical University of GrazRecruiting
-
AQILION ABCompletedEosinophilic Esophagitis (EoE)United Kingdom
-
Regeneron PharmaceuticalsSanofiActive, not recruitingEosinophilic Esophagitis (EoE)United States, Canada
-
ShireTakeda Development Center Americas, Inc.TerminatedEosinophilic Esophagitis (EoE)United States
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
-
ShireCompleted
-
ShireCompletedEosinophilic Esophagitis (EoE)United States
Clinical Trials on NIOX MINO® Airway Inflammation Monitor
-
Aerocrine ABCompletedAsthmaSweden, United Kingdom
-
Aerocrine ABCompleted
-
Wake Forest UniversityAerocrine ABTerminatedChronic Obstructive Pulmonary DiseaseUnited States
-
Aerocrine ABCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
Aerocrine ABCompleted
-
Julio RamirezUniversity of LouisvilleTerminatedOsteomyelitisUnited States